Literature DB >> 30085982

Time to advocate for better science, and better treatments for women.

Caroline M Mitchell1, Susan D Reed, Katherine A Guthrie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30085982      PMCID： PMC6136944          DOI： 10.1097/GME.0000000000001175

Source DB:  PubMed          Journal:  Menopause        ISSN： 1072-3714            Impact factor:   2.953


× No keyword cloud information.
  29 in total

1.  Comparative study: Replens versus local estrogen in menopausal women.

Authors:  L E Nachtigall
Journal:  Fertil Steril       Date:  1994-01       Impact factor: 7.329

2.  Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.

Authors:  D Portman; S Palacios; R E Nappi; A O Mueck
Journal:  Maturitas       Date:  2014-03-12       Impact factor: 4.342

3.  Are women with urogenital atrophy symptomatic?

Authors:  G Willy Davila; Anita Singh; Ifigenia Karapanagiotou; Sherry Woodhouse; Karen Huber; Stephen Zimberg; Jeffrey Seiler; Stacy L Kopka
Journal:  Am J Obstet Gynecol       Date:  2003-02       Impact factor: 8.661

4.  Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors.

Authors:  Alison J Huang; Elya E Moore; Edward J Boyko; Delia Scholes; Feng Lin; Eric Vittinghoff; Stephan D Fihn
Journal:  Menopause       Date:  2010 Jan-Feb       Impact factor: 2.953

5.  Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally.

Authors:  Gloria Bachmann; Céline Bouchard; Diana Hoppe; Radhika Ranganath; Corrado Altomare; Alberta Vieweg; Jay Graepel; Eileen Helzner
Journal:  Menopause       Date:  2009 Jul-Aug       Impact factor: 2.953

6.  17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis.

Authors:  J E Rioux; C Devlin; M M Gelfand; W M Steinberg; D S Hepburn
Journal:  Menopause       Date:  2000 May-Jun       Impact factor: 3.310

7.  Intravaginally applied oxytocin improves post-menopausal vaginal atrophy.

Authors:  Shahla H Al-Saqi; Kerstin Uvnäs-Moberg; Aino F Jonasson
Journal:  Post Reprod Health       Date:  2015-05-19

8.  A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.

Authors:  Robin Kroll; David F Archer; Yuhua Lin; Vilma Sniukiene; James H Liu
Journal:  Menopause       Date:  2018-02       Impact factor: 2.953

9.  The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.

Authors:  Ginger D Constantine; James A Simon; James H Pickar; David F Archer; Harvey Kushner; Brian Bernick; Gina Gasper; Shelli Graham; Sebastian Mirkin
Journal:  Menopause       Date:  2017-04       Impact factor: 2.953

Review 10.  Local oestrogen for vaginal atrophy in postmenopausal women.

Authors:  Anne Lethaby; Reuben Olugbenga Ayeleke; Helen Roberts
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31
View more
  1 in total

1.  Convergent-Divergent Validity and Correlates of the Day-to-Day Impact of Vaginal Aging Domain Scales in the MsFLASH Vaginal Health Trial.

Authors:  Mary M Hunter; Katherine A Guthrie; Joseph C Larson; Susan D Reed; Caroline M Mitchell; Susan J Diem; Andrea Z LaCroix; Alison J Huang
Journal:  J Sex Med       Date:  2019-12-04       Impact factor: 3.802
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.